NeoSan gets US rights to Lilly's Darvon and Darvocet N
Executive Summary
AaiPharma's commercialization unit NeoSan Pharmaceuticals acquired US rights to Eli Lilly's Darvon (propoxyphene hydrochloride) and Darvocet N (propoxyphene napsylate with acetaminophen) line of pain management products.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice